Tylenol Gains On COX-2 Fallout, Drives J&J Consumer Sales
This article was originally published in The Tan Sheet
Executive Summary
Tylenol first-quarter sales benefited from the publicity surrounding COX-2 safety issues, according to Johnson & Johnson